CASP3 and ovarian carcinoma: Ding et al. [25] suggested that in the MMR-deficient ovarian cancer cell line A2780MNU1, MLH1 overexpression significantly reduced cell survival and proliferation, with a high percentage of cells displaying active caspase-3 after drug treatment.